Answers are grounded in this paper and cite their sources.
Introduction: Agglutination in red blood cells can be associated with a number of complications. These complications are related to the amount of antibody titer produced. Some genetic factors, such as HLA-DRB1*15:03 and HLA-DRB1*09:01 alleles, are involved in the production of antibody titers. Aims and Objectives: The aim of this study was to investigate the causative allele of the high and dangerous titer antibodies (anti-A and anti-B) among blood donors in Bandar Abbas. Methods: Antibody A and B levels were measured by titration on 121 serum samples of blood type O donors in 2 incubations at room temperature and anti-human globulin tube method. Titers higher than 512 and the same number of participants with a titer of <64 were selected and whether or not genotypes 901 and 1503 were found. After titration, sample DNAs were extracted, and then, amplification-refractory mutation system–polymerase chain reaction was used to determine allelic polymorphism. Results: The antibody titer was found to be elevated in this study, but there was no significant relationship between the presence or absence of genotype 901 (HLA-DRB1*9:01) and genotype 1503 (HLA-DRB1*15:03) and the high titer of anti-A and anti-B antibodies. Discussion and Conclusion: Finally, studies have shown that a critical titer should be determined for antibodies to the ABO blood system in order to provide blood transfusion safety. However, the higher the titers of anti-A and anti-B, the safety of transfusion medicine is also provided.
No takes yet. Share an insight, caveat, or question.
Pourfathollah et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: